The potential of mRNA science and the next generation of vaccines in patients with primary immunodeficiencies
This Moderna sponsored symposium on Friday 14 October 12:15-13:45 will explore mRNA technology within the context of vaccine development
and its role in protecting patients with immunodeficiencies.
Professor Karin Loré
Chair
The session will be chaired by Professor Karin Loré, who, along with our expert faculty, will consider the challenges experienced by patients with immunodeficiencies in response to viral infections and the role of vaccination in addressing these challenges.
Dr Paolo Martini
Dr Paolo Martini will first introduce mRNA science and platform technology, considering its use in development of a vaccine for COVID-19, as well as the potential of mRNA therapeutics in other areas such as rare diseases.
Dr Kimberley Gilmour
Dr Kimberley Gilmour will then familiarise us with the impact of primary immunodeficiencies on the immune system and the subsequent susceptibility to viral infections. She will share her insights on the burden, prevention, and management of respiratory and non-respiratory diseases in patients with primary immunodeficiencies.
Professor Paul Moss
Finally, the response of patients with primary immunodeficiencies to vaccines, lessons learnt from mRNA COVID-19 vaccines,
and guidance on vaccination in these patients will be addressed by Professor Paul Moss.
The symposium will conclude with a live Q&A session with the faculty moderated by Professor Loré.
This session is not included in main event CME/CPD credits.
